hCAIX/XII-IN-6 

hCAIX/XII-IN-6 is an orally active carbonic anhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with K_i values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA)^[1].

hCAIX/XII-IN-6 has inhibition activitr for human CA isoforms hCA I, II, IV, IX, and XII with K_i values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively^[1][1].
hCAIX/XII-IN-6 (150 μM) exhibits a weaker H2S releas^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

hCAIX/XII-IN-6 (oral; 1, 10, 30 mg/kg; single) completely reverts the pain state 45 min after administration and enhances antihyperalgesic effect in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

601.74

C₂₆H₂₃N₃O₆S₄

3031666-31-3

O=C(N(CC1=CC=C([N+]([O-])=O)C=C1OC)CCC2=CC=C(S(=O)(N)=O)C=C2)C3=CC=C(C4=CSSC4=S)C=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Alessandro Bonardi, et al. Development of Hydrogen Sulfide-Releasing Carbonic Anhydrases IX- and XII-Selective Inhibitors with Enhanced Antihyperalgesic Action in a Rat Model of Arthritis. J Med Chem. 2022 Sep 19.  [Content Brief]